Key Takeaways
- Shares of UNH advanced 1.5% during Monday’s session, reaching an intraday peak of $283.30 and settling at $281.46.
- CMS unveiled a final Medicare Advantage rate hike of 2.48% for 2027, dramatically higher than the 0.09% preliminary figure released in January.
- The revised rate will deliver an additional $13 billion in government reimbursements to health insurers throughout the next year.
- Raymond James elevated UNH to “outperform” from “market perform” before the company’s Q1 earnings report scheduled for April 21, establishing a $330 target price.
- Humana shares soared 11% in premarket activity following the Medicare announcement; both UNH and CVS Health climbed over 6% before market open.
Shares of UNH began Monday’s trading at $277.26, climbed to $283.30 during the session, and finished at $281.46 — representing a 1.5% advance.
UnitedHealth Group Incorporated, UNH
The healthcare giant has declined approximately 22% during the past six months and remains positioned beneath both its 50-day moving average at $283.03 and its 200-day moving average at $319.62. Wall Street’s average analyst target price stands at $363.38.
Following Monday’s market close, the Centers for Medicare and Medicaid Services (CMS) unveiled its definitive 2027 payment structure for Medicare Advantage programs. The rate settled at a 2.48% average boost — substantially exceeding the 0.09% preliminary figure introduced in January that had shaken investor confidence across the sector.
That preliminary January announcement triggered selloffs in UNH and Humana when initially disclosed. Market participants had been closely monitoring whether the final determination would show improvement.
The elevated rate represents $13 billion in supplementary government funding flowing to insurers throughout the coming year. Both UNH and CVS Health, Aetna’s parent organization, jumped more than 6% during premarket activity after the disclosure. Humana experienced an 11% surge.
Why Medicare Advantage Matters for Insurers
Medicare Advantage serves as the private-sector option to conventional Medicare and currently provides coverage for approximately 35 million Americans, according to health policy organization KFF. Participation has expanded consistently and now surpasses traditional Medicare enrollment.
For major insurers like UnitedHealth, this program represents a fundamental revenue stream. A near-flat rate adjustment — while medical expenditures are climbing 7% to 9% yearly — would have functioned as an effective reduction, according to analysis from the Better Medicare Alliance.
Mizuho’s analyst Jared Holz characterized the 2.48% final determination as “certainly better than the government’s initial rate decision,” noting it establishes a foundation for margin improvement in the upcoming year if insurers maintain their focus on benefit adjustments and cost management.
TD Cowen analyst Ryan Langston had anticipated a smaller increase between 1% and 1.5%, making the actual figure a positive surprise compared to certain projections.
Cross-party political pressure had complicated the rate forecast. Leaders from both major political parties have expressed concerns regarding insurers securing elevated reimbursements through diagnostic coding practices — commonly referred to as risk adjustment. The previous administration initiated stricter oversight of these mechanisms, and the current administration’s January preliminary proposal indicated ongoing regulatory attention.
First Quarter Results Due April 21
Raymond James raised its rating on UNH from “market perform” to “outperform” on April 1, assigning a $330 valuation target. The investment firm pointed to possibilities for leadership to demonstrate operational stabilization approaching the earnings announcement.
Barclays maintains an “overweight” stance with a $327 objective. Mizuho and Leerink Partners similarly rate the stock “outperform,” establishing targets of $350 and $345 respectively.
Among the 28 analysts tracking the company, 18 recommend Buy, seven suggest Hold, and two advise Sell. The MarketBeat consensus rating is Moderate Buy.
First quarter financial results are scheduled for April 21. During the fourth quarter, UNH reported $2.11 earnings per share, surpassing the analyst consensus of $2.09. Revenue totaled $113.73 billion, reflecting 12.3% year-over-year growth. Management has provided full-year 2026 guidance of $17.75 EPS.
UNH distributes a quarterly dividend of $2.21, yielding 3.1% annually at current market prices.
Institutional investors control 87.86% of outstanding shares, with recent stake increases from Norges Bank, Berkshire Hathaway, and T. Rowe Price.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
